

# Adults with complex needs: social work interventions including assessment, care management and support

*NICE guideline number tbc*

*Methods*

*November 2021*

**Supplement 1: Methods**

*Draft for Consultation*

*Developed by the National Guideline Alliance which is part of the Royal College of Obstetricians and Gynaecologists*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE, 2021. All rights reserved. Subject to [Notice of rights](#).

ISBN:

# Contents

<b>Development of the guideline</b> .....	<b>5</b>
Remit.....	5
<b>Methods</b> .....	<b>6</b>
Developing the review questions and outcomes .....	6
Searching for evidence .....	8
Scoping search.....	8
Systematic literature search .....	8
Economic systematic literature search .....	9
Reviewing research evidence .....	10
Systematic review process .....	10
Type of studies and inclusion/exclusion criteria .....	10
Methods of combining evidence .....	11
Data synthesis for intervention studies .....	11
Data synthesis for qualitative reviews .....	12
Data synthesis for mixed methods reviews .....	13
Appraising the quality of evidence .....	13
Intervention studies .....	13
Qualitative studies .....	17
Reviewing economic evidence .....	20
Appraising the quality of economic evidence .....	21
Economic modelling .....	21
Cost effectiveness criteria .....	21
Developing recommendations .....	22
Guideline recommendations .....	22
Research recommendations.....	22
Validation process .....	22
Updating the guideline.....	23
Funding .....	23
<b>References</b> .....	<b>24</b>

# 1 Development of the guideline

## 2 Remit

3 The National Institute for Health and Care Excellence (NICE) commissioned the  
4 National Guideline Alliance (NGA) to develop a guideline about social work  
5 interventions for adults with complex needs.

6 To see “What this guideline covers” and “What this guideline does not cover” please  
7 see the final scope of the guideline on the [NICE website](#).

# 1 Methods

2 This guideline was developed using the methods described in the [Developing NICE](#)  
3 [guidelines: the manual](#).

4 Declarations of interest were recorded according to the [NICE conflicts of interest](#)  
5 [policy](#).

## 6 Developing the review questions and outcomes

7 The review questions developed for this guideline were based on the key areas  
8 identified in the guideline [scope](#). They were drafted by the NGA technical team, and  
9 refined and validated by the guideline committee.

10 The review questions were based on the following frameworks:

- 11 • population, intervention, comparator and outcome (PICO) for reviews of  
12 interventions
- 13 • qualitative reviews – using population, phenomenon of interest and context  
14 (PICo)

15 Full literature searches, critical appraisals and evidence reviews were completed for  
16 all review questions.

17 The review questions and evidence reviews corresponding to each question (or  
18 group of questions) are summarised below.

19 **Table 1: Summary of review questions and index to evidence reviews**

Evidence review	Review question	Type of review
[A] Needs assessment	[A1] What is the effectiveness of social work approaches to assessing and reviewing complex care and support needs (including strengths-based approaches)?  [A2] Based on the views and experiences of everyone involved, what works well and what could be improved about social work assessments of complex care and support needs?	Mixed, intervention and qualitative
[B] Risk assessment	[B1] What is the effectiveness of social work approaches to assessing and reviewing risk with adults with complex needs?  [B2] Based on the views and experiences of everyone involved, what works well and	Mixed, intervention and qualitative

Evidence review	Review question	Type of review
	what could be improved about risk assessment with adults with complex needs?	
[C] Supporting changing needs	<p>[C1] What is the effectiveness of case management and care planning approaches in social work (in relation to changing needs, wishes and capabilities)?</p> <p>[C2] Based on the views and experiences of everyone involved, what works well and what can be improved about case management and care planning approaches in social work (in relation to changing needs, wishes and capabilities)?</p>	Mixed, intervention and qualitative
[D] Support during an escalation of need	<p>[D1] What is the effectiveness of case management and care planning when there is an unplanned escalation of need, or to provide urgent support if needs do escalate?</p> <p>[D2] Based on the views and experiences of everyone involved, what works well and what can be improved in case management and care planning when there is an unplanned escalation of need, or to provide urgent support if needs do escalate?</p>	Mixed, intervention and qualitative
[E] Integrated working	<p>[E1] What is the effectiveness of integrated working among registered social workers and other practitioners to support adults with complex needs?</p> <p>[E2] Based on the views and experiences of everyone involved, what are the facilitators and barriers to integrated working between registered social workers and other practitioners to support adults with complex needs?</p>	Mixed, intervention and qualitative
[F] Individual or family casework	[F1] What is the effectiveness of social work approaches to	Mixed, intervention and qualitative

Evidence review	Review question	Type of review
	individual and family casework for adults with complex needs?  [F2] Based on the views and experiences of everyone involved, what works well and what could be improved about social work approaches to individual and family casework for adults with complex needs?	
[G] Helping people connect with local communities	[G1] What is the effectiveness of social and community support approaches (including peer support) in promoting social inclusion of adults with complex needs?  [G2] Based on the views and experiences of everyone involved, what works well and what could be improved about social and community support (including peer support) to promote social inclusion for adults with complex needs?	Mixed, intervention and qualitative

1 <sup>1</sup>Original health economic analysis conducted

2 The [COMET database](#) was searched for core outcome sets relevant to this guideline.

3 Additional information related to development of the guideline is contained in:

- 4 • Supplement 1 (Methods; this document)
- 5 • Supplement 2 (Economics)
- 6 • Supplement 3 (NGA staff list).

## 7 Searching for evidence

### 8 Scoping search

9 During the scoping phase, searches were conducted for previous guidelines,  
10 economic evaluations, health technology assessments, systematic reviews and  
11 randomised controlled trials.

### 12 Systematic literature search

13 Systematic literature searches were undertaken to identify published evidence  
14 relevant to each review question.

15 Databases were searched using subject headings, free-text terms and, where  
16 appropriate, study type filters. Where possible, searches were limited to retrieve  
17 studies published in English. All the searches were conducted in the following



1 databases: Medline, Medline-in-Process, Cochrane Central Register of Controlled  
2 Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR), Database of  
3 Abstracts of Reviews of Effects (DARE), Health Technology Assessments (HTA) and  
4 Embase, Applied Social Sciences Index and Abstracts (ASSIA), International  
5 Bibliography of the Social Sciences (IBSS), Sociological Abstracts, Social Services  
6 Abstracts, Social Policy and Practice, Social Care Online. For the qualitative review  
7 questions, PsycInfo, EmCare and CINAHL were also searched.

8 Searches were run once for all reviews during development.

9 For the qualitative questions a single combined search, using the population search  
10 terms used in the evidence reviews combined with a qualitative studies filter, was  
11 conducted for all topics (A2, B2, C2, D2, E2, F2, G2).

12 For the quantitative questions individual searches were conducted for each of the  
13 topics (A1, B1, C1, D1, E1, F1, G1).

14 Searches for the following questions were updated in June, eight weeks in advance  
15 of the final committee meeting.

- 16 • [A1] What is the effectiveness of social work approaches to assessing and  
17 reviewing complex care and support needs (including strengths-based  
18 approaches)?
- 19 • [B1] What is the effectiveness of social work approaches to assessing and  
20 reviewing risk with adults with complex needs?
- 21 • [D1] What is the effectiveness of case management and care planning when  
22 there is an unplanned escalation of need, or to provide urgent support if needs  
23 do escalate?

24 Details of the search strategies, including the study-design filters used and  
25 databases searched, are provided in Appendix B of each evidence review.

## 26 **Economic systematic literature search**

27 Systematic literature searches were also undertaken to identify published economic  
28 evidence. Databases were searched using subject headings, free-text terms and,  
29 where appropriate, an economic evaluations search filter.

30 A single search, using the population search terms used in the evidence reviews  
31 combined with economic evaluations and health utility values search filters, was  
32 conducted in Medline, Medline in Process, Cochrane Central Register of Controlled  
33 Trials (CCTR), Embase, Applied Social Sciences Index & Abstracts (ASSIA),  
34 International Bibliography of the Social Sciences (IBSS), Sociological Abstracts,  
35 Social Services Abstracts, PsycInfo, Social Policy and Practice, Social Care  
36 Online, EmCare and CINAHL. Where possible, searches were limited to studies  
37 published in English.

38 As with the general literature searches, the economic literature searches were  
39 updated in June, eight weeks in advance of the final committee meeting before  
40 consultation on the draft guideline.

41 Details of the search strategies, including the study-design filter used and databases  
42 searched, are provided in Supplement 2 (Health economics).

## 1 Quality assurance

2 Search strategies were quality assured by cross-checking reference lists of relevant  
3 studies, analysing search strategies from published systematic reviews and asking  
4 members of the committee to highlight key studies. The principal search strategies  
5 for each search were also quality assured by a second information scientist using an  
6 adaptation of the PRESS 2015 Guideline Evidence-Based Checklist  
7 (McGowan 2016). In addition, all publications highlighted by stakeholders at the time  
8 of the consultation on the draft scope were considered for inclusion.

## 9 Reviewing research evidence

### 10 Systematic review process

11 The evidence was reviewed in accordance with the following approach.

- 12 • Potentially relevant articles were identified from the search results for each  
13 review question by screening titles and abstracts. Full-text copies of the articles  
14 were then obtained.
- 15 • Full-text articles were reviewed against pre-specified inclusion and exclusion  
16 criteria in the review protocol (see Appendix A of each evidence review).
- 17 • Key information was extracted from each article on study methods and results,  
18 in accordance with factors specified in the review protocol. The information was  
19 presented in a summary table in the corresponding evidence review and in a  
20 more detailed evidence table (see Appendix D of each evidence review).
- 21 • Included studies were critically appraised using an appropriate checklist as  
22 specified in [Developing NICE guidelines: the manual](#). Further detail on  
23 appraisal of the evidence is provided below.
- 24 • Summaries of evidence by outcome and qualitative evidence by theme were  
25 presented in the corresponding evidence review and discussed by the  
26 committee.

27 Review questions were subject to dual screening and study selection through a 10%  
28 random sample of articles, as described in the review protocols. Any discrepancies  
29 were resolved by discussion between the first and second reviewers or by reference  
30 to a third (senior) reviewer.

31 Drafts of all evidence reviews were quality assured by a senior reviewer.

### 32 Type of studies and inclusion/exclusion criteria

33 Inclusion and exclusion of studies was based on criteria specified in the  
34 corresponding review protocol.

35 Systematic reviews with meta-analyses or meta-syntheses were considered to be the  
36 highest quality evidence that could be selected for inclusion.

37 For the intervention components of the reviews, randomised controlled trials (RCTs)  
38 were prioritised for inclusion because they are considered to be the most robust type  
39 of study design that could produce an unbiased estimate of intervention effects. Non-  
40 randomised controlled trials were also considered for inclusion. In the absence of  
41 experimental studies (randomised or non-randomised assignment) reporting critical

1 outcomes, observational studies (such as prospective cohort studies) were also  
2 considered, with studies using multivariate analyses prioritised over those using  
3 univariate methods of analysis.

4 For the qualitative components of the reviews, studies using focus groups, structured  
5 interviews or semi-structured interviews were considered for inclusion. Where  
6 qualitative evidence was sought, data from surveys or other types of questionnaire  
7 were considered for inclusion only if they provided data from open-ended questions,  
8 but not if they reported only quantitative data.

9 For both the quantitative and qualitative components of the reviews, studies  
10 conducted in the UK were prioritised as generating the most relevant evidence for the  
11 purposes of making recommendations. However in the absence of UK studies or  
12 where there were too few UK studies to support decision making, studies from high  
13 income countries from Europe plus Australia, New Zealand, Canada and South  
14 Africa were considered for inclusion.

15 The committee was consulted about any uncertainty regarding inclusion or exclusion  
16 of studies. A list of excluded studies for each review question, including reasons for  
17 exclusion is presented in Appendix J of the corresponding evidence review.

18 Narrative reviews, posters, letters, editorials, comment articles, unpublished studies  
19 and studies published in languages other than English were excluded. Conference  
20 abstracts were not considered for inclusion because conference abstracts typically  
21 do not have sufficient information to allow for full critical appraisal.

## 22 **Methods of combining evidence**

23 When planning reviews (through preparation of protocols), the following approaches  
24 for data synthesis were discussed and agreed with the committee.

### 25 **Data synthesis for intervention studies**

#### 26 ***Pairwise meta-analysis***

27 No meta-analysis was conducted for this guideline because either the interventions  
28 were not sufficiently similar or where interventions were similar, different outcomes  
29 were measured. Data from single studies were analysed where possible using  
30 Cochrane Review Manager (RevMan5) software.

31 For dichotomous outcomes, such as care contacts, the Mantel–Haenszel method  
32 with a fixed effect model was used to calculate risk ratios (RRs).

33 For continuous outcomes, measures of central tendency (mean) and variation  
34 (standard deviation; SD) are required for analysis. Data for continuous outcomes,  
35 such as quality of life, were analysed using an inverse-variance method for mean  
36 differences from final scores only between intervention groups, or mean change  
37 scores between groups. Where SDs were not reported for each intervention group,  
38 the standard error (SE) of the mean difference was calculated from other reported  
39 statistics (p values or 95% confidence intervals; CIs) and then analysis was  
40 conducted as described above.

41 If a study reported only the summary statistic and 95% CI the generic-inverse  
42 variance method was used to enter data into RevMan5. If the control event rate was

1 reported this was used to generate the absolute risk difference in GRADEpro. If  
2 multivariable analysis was used to derive the summary statistic but no adjusted  
3 control event rate was reported, no absolute risk difference was calculated.

4 When evidence was based on studies that reported descriptive data or medians with  
5 interquartile ranges or p values, this information was included in the corresponding  
6 GRADE tables (see below) without calculating relative or absolute effects.  
7 Consequently, certain aspects of quality assessment such as imprecision of the  
8 effect estimate could not be assessed as per standard methods for this type of  
9 evidence and ratings based on sample size cut-offs were considered instead.

## 10 **Data synthesis for qualitative reviews**

11 In the qualitative components of the reviews, where possible, a meta-synthesis was  
12 conducted to combine evidence from more than one study into a theme or sub-  
13 theme. Whenever studies identified a qualitative theme relevant to the protocol, this  
14 was extracted and the main characteristics were summarised. When all themes had  
15 been extracted from studies, common concepts were categorised and tabulated. This  
16 included information on how many studies had contributed to each theme identified  
17 by the NGA technical team.

18 The technical team were guided in their data extraction, synthesis and formulation of  
19 review findings, or themes, by a framework of phenomena of interest developed by  
20 the guideline committee. This framework consisted of the themes that the committee  
21 anticipated would be covered by the included studies and these were set out a priori  
22 in the corresponding review protocol. As well as guiding the data extraction and  
23 synthesis, the framework also underpinned the approach referred to in the protocol  
24 as thematic saturation. Essentially, data or themes from included studies would not  
25 be extracted if they contributed to review findings which were judged to be 'adequate'  
26 and 'coherent' following assessment using the GRADE-CERQual approach; that is,  
27 they were not downgraded for either domain. Themes identified from the included  
28 studies, which were not set out in the protocol but which were considered relevant to  
29 answering the review question, were also extracted and the same approach to  
30 'thematic saturation' would have been applied. Thematic saturation was not reached  
31 for any themes in any of the qualitative components of the reviews in this guideline.  
32 Therefore, all relevant data from all included qualitative studies were extracted and  
33 analysed.

34 Themes from individual studies were integrated into a wider context and, when  
35 possible, overarching categories of themes with sub-themes were identified. Themes  
36 were derived from data presented in individual studies. When themes were extracted  
37 from 1 primary study only, theme names used in the guideline mirrored those in the  
38 source study. However, when themes were based on evidence from multiple studies,  
39 the theme names were assigned by the NGA technical team. The names of  
40 overarching categories of themes were also assigned by the NGA technical team.

41 Emerging themes were placed into a thematic map representing the relationship  
42 between themes and overarching categories. The purpose of such a map is to show  
43 relationships between overarching categories and associated themes.

## 1 Data synthesis for mixed methods reviews

2 All the reviews were mixed methods reviews, reporting effectiveness as well as  
3 qualitative data relating to the same specific area. The NGA technical team  
4 conducted the data analysis, critical appraisal and GRADE/GRADE-CERQual  
5 profiles (described in the next section) separately and in parallel for the quantitative  
6 and qualitative data. The review team then completed a further layer of interpretation  
7 of the findings to help committees understand how the qualitative evidence could  
8 help to explain or contextualise the quantitative findings. This is presented in a table  
9 in each evidence report, which displays qualitative themes or sub themes, matched  
10 to relevant quantitative findings as well as an explanation about how the qualitative  
11 evidence might explain the quantitative results. The committee then discussed the  
12 synthesis of these data through their discussions of the evidence. Their interpretation  
13 of the relationship between the quantitative and qualitative data is described in the  
14 committee's discussion of the evidence section of all the mixed methods reviews.

## 15 Appraising the quality of evidence

### 16 Intervention studies

#### 17 *Pairwise meta-analysis*

### 18 GRADE methodology for intervention reviews

19 For intervention reviews, the evidence for outcomes from included RCTs and  
20 comparative non-randomised studies was evaluated and presented using the  
21 Grading of Recommendations Assessment, Development and Evaluation (GRADE)  
22 methodology developed by the international [GRADE working group](#).

23 When GRADE was applied, software developed by the GRADE working group  
24 (GRADEpro) was used to assess the quality of each outcome, taking account of  
25 individual study quality factors and any meta-analysis results. Results were  
26 presented in GRADE profiles (GRADE tables).

27 The selection of outcomes for each review question was agreed during development  
28 of the associated review protocol in discussion with the committee. The evidence for  
29 each outcome was examined separately for the quality elements summarised in  
30 Table 2. Criteria considered in the rating of these elements are discussed below.  
31 Each element was graded using the quality ratings summarised in Table 3. Footnotes  
32 to GRADE tables were used to record reasons for grading a particular quality  
33 element as having a 'serious' or 'very serious' quality issue. The ratings for each  
34 component were combined to obtain an overall assessment of quality for each  
35 outcome as described in Table 4.

36 The initial quality rating was based on the study design: RCTs start as 'high' quality  
37 evidence as do NRS assessed by ROBINS-I and, other non-randomised studies start  
38 as 'low' quality evidence. The rating was then modified according to the assessment  
39 of each quality element (Table 2). Each quality element considered to have a  
40 'serious' or 'very serious' quality issue was downgraded by 1 or 2 levels respectively  
41 (for example, evidence starting as 'high' quality was downgraded to 'moderate' or  
42 'low' quality). In addition, there was a possibility to upgrade evidence from non-  
43 randomised studies (provided the evidence for that outcome had not previously been

1 downgraded) if there was a large magnitude of effect, a dose–response gradient, or if  
2 all plausible confounding would reduce a demonstrated effect or suggest a spurious  
3 effect when results showed no effect.

4 **Table 2: Summary of quality elements in GRADE for intervention reviews**

Quality element	Description
Risk of bias ('Study limitations')	This refers to limitations in study design or implementation that reduce the internal validity of the evidence
Inconsistency	This refers to unexplained heterogeneity in the results
Indirectness	This refers to differences in study populations, interventions, comparators or outcomes between the available evidence and inclusion criteria specified in the review protocol
Imprecision	This occurs when a study has few participants or few events of interest, resulting in wide confidence intervals that cross minimally important thresholds
Publication bias	This refers to systematic under- or over-estimation of the underlying benefit or harm resulting from selective publication of study results

5 **Table 3: GRADE quality ratings (by quality element)**

Quality issues	Description
None or not serious	No serious issues with the evidence for the quality element under consideration
Serious	Issues with the evidence sufficient to downgrade by 1 level for the quality element under consideration
Very serious	Issues with the evidence sufficient to downgrade by 2 levels for the quality element under consideration

6 **Table 4: Overall quality of the evidence in GRADE (by outcome)**

Overall quality grading	Description
High	Further research is very unlikely to change the level of confidence in the estimate of effect
Moderate	Further research is likely to have an important impact on the level of confidence in the estimate of effect and may change the estimate
Low	Further research is very likely to have an important impact on the level of confidence in the estimate of effect and is likely to change the estimate
Very low	The estimate of effect is very uncertain

7 *Assessing risk of bias in intervention reviews*

8 Bias is a systematic error, or consistent deviation from the truth in results obtained.  
9 When a risk of bias is present the true effect can be either under- or over-estimated.

10 Risk of bias in RCTs was assessed using the Cochrane risk of bias tool (2.0) (see  
11 [Appendix H in Developing NICE guidelines: the manual](#)).

- 1 The Cochrane risk of bias tool (2.0) assesses the following possible sources of bias:
- 2 • the randomisation process
  - 3 • deviations from intended interventions
  - 4 • missing outcome data
  - 5 • measurement of the outcomes
  - 6 • selection of the reported result.

7 A study with a poor methodological design does not automatically imply high risk of  
8 bias; the bias is considered individually for each outcome and it is assessed whether  
9 the chosen design and methodology will impact on the estimation of the intervention  
10 effect.

11 More details about the Cochrane risk of bias tool (2.0) can be found in Section 8 of  
12 the [Cochrane Handbook for Systematic Reviews of Interventions](#) (Higgins 2011).

13 For non-randomised studies the ROBINS-I checklist was used ([see Appendix H in](#)  
14 [Developing NICE guidelines: the manual](#)).

#### 15 *Assessing inconsistency in intervention reviews*

16 Inconsistency refers to unexplained heterogeneity in results of meta-analysis. When  
17 estimates of treatment effect vary widely across studies (that is, there is  
18 heterogeneity or variability in results), this suggests true differences in underlying  
19 effects. Inconsistency is, thus, only truly applicable when statistical meta-analysis is  
20 conducted (that is, results from different studies are pooled). When outcomes were  
21 derived from a single study the rating 'no serious inconsistency' was used when  
22 assessing this domain, as per GRADE methodology (Santesso 2016).

23 For this guideline there were no pooled data in any of the quantitative components of  
24 the evidence reviews and therefore no heterogeneity to explore, for example through  
25 subgroup analysis. All outcomes were judged to have 'no serious inconsistency' and  
26 were not downgraded for this GRADE domain.

#### 27 *Assessing indirectness in intervention reviews*

28 Directness refers to the extent to which populations, interventions, comparisons and  
29 outcomes reported in the evidence are similar to those defined in the inclusion  
30 criteria for the review and was assessed by comparing the PICO elements in the  
31 studies to the PICO defined in the review protocol. Indirectness is important when  
32 such differences are expected to contribute to a difference in effect size, or may  
33 affect the balance of benefits and harms considered for an intervention.

#### 34 *Assessing imprecision and importance in intervention reviews*

35 Imprecision in GRADE methodology refers to uncertainty around the effect estimate  
36 and whether or not there is an important difference between interventions (that is,  
37 whether the evidence clearly supports a particular recommendation or appears to be  
38 consistent with several candidate recommendations). Therefore, imprecision differs  
39 from other aspects of evidence quality because it is not concerned with whether the  
40 point estimate is accurate or correct (has internal or external validity). Instead, it is  
41 concerned with uncertainty about what the point estimate actually represents. This  
42 uncertainty is reflected in the width of the CI.

1 The 95% CI is defined as the range of values within which the population value will  
2 fall on 95% of repeated samples, were the procedure to be repeated. The larger the  
3 study, the smaller the 95% CI will be and the more certain the effect estimate.

4 Imprecision was assessed in the guideline evidence reviews by considering whether  
5 the width of the 95% CI of the effect estimate was relevant to decision making,  
6 considering each outcome independently. This is illustrated in Figure 1, which  
7 considers a positive outcome for the comparison of two treatments. Three decision-  
8 making zones can be differentiated, bounded by the thresholds for minimal  
9 importance (minimally important differences; MIDs) for benefit and harm.


10 When the CI of the effect estimate is wholly contained in 1 of the 3 zones there is no  
11 uncertainty about the size and direction of effect, therefore, the effect estimate is  
12 considered precise; that is, there is no imprecision.

13 When the CI crosses 2 zones, it is uncertain in which zone the true value of the effect  
14 estimate lies and therefore there is uncertainty over which decision to make. The CI  
15 is consistent with 2 possible decisions, therefore, the effect estimate is considered to  
16 be imprecise in the GRADE analysis and the evidence is downgraded by 1 level  
17 ('serious imprecision').

18 When the CI crosses all 3 zones, the effect estimate is considered to be very  
19 imprecise because the CI is consistent with 3 possible decisions and there is  
20 therefore a considerable lack of confidence in the results. The evidence is therefore  
21 downgraded by 2 levels in the GRADE analysis ('very serious imprecision').

22 Implicitly, assessing whether a CI is in, or partially in, an important zone, requires the  
23 guideline committee to estimate an MID or to say whether they would make different  
24 decisions for the 2 confidence limits.

25 **Figure 1: Assessment of imprecision and importance in intervention reviews**  
26 **using GRADE**



27  
28 *MID, minimally important difference*

29 *Defining minimally important differences for intervention reviews*

30 The committee was not aware of any recognised or acceptable MIDs in the published  
31 literature and community relevant to the review questions under consideration. They  
32 therefore agreed to use the GRADE default MIDs to assess imprecision.



1 For dichotomous outcomes minimally important thresholds for a RR of 0.8 and 1.25  
2 respectively were used as default MIDs in the guideline. The committee also chose to  
3 use 0.8 and 1.25 as the MIDs for ORs & HRs in the absence of published or  
4 accepted MIDs. There were no instances of low event rates for any outcomes so  
5 Peto OR were not used. There were also no instances of zero events in either arm.  
6 However in the quantitative component of review C, for some data, only p-values  
7 were reported and since there are no default MIDs for p-values, imprecision was  
8 assessed based on sample size using 200 and 400 as cut-offs for very serious and  
9 serious imprecision respectively. The committee used these numbers based on  
10 commonly used optimal information size thresholds.

11 The same thresholds were used as default MIDs in the guideline for all dichotomous  
12 outcomes considered in the intervention components of the evidence reviews. For  
13 continuous outcomes default MIDs are equal to half the median SD of the control  
14 groups at baseline (or at follow-up if the SD is not available a baseline).

#### 15 *Assessing publication bias in intervention reviews*

16 None of the data were pooled so the committee subjectively assessed the likelihood  
17 of publication bias based on factors such as whether studies were funded by industry  
18 and the propensity for publication bias in the topic area.

### 19 **Qualitative studies**

#### 20 ***GRADE-CERQual methodology for qualitative reviews***

21 For the qualitative components of the reviews an adapted GRADE Confidence in the  
22 Evidence from Reviews of Qualitative research (GRADE-CERQual) approach (Lewin  
23 2015) was used. In this approach the quality of evidence is considered according to  
24 themes in the evidence. The themes may have been identified in the primary studies  
25 or they may have been identified by considering the reports of a number of studies.  
26 Quality elements assessed using GRADE-CERQual are listed and defined in Table  
27 5. Each element was graded using the levels of concern summarised in Table 6.

28 The ratings for each component were combined (as with other types of evidence) to  
29 obtain an overall assessment of quality for each theme as described in Table 7.  
30 'Confidence' in this context refers to the extent to which the review finding is a  
31 reasonable representation of the phenomenon of interest set out in the protocol.  
32 Similar to other types of evidence all review findings start off with 'high confidence'  
33 and are rated down by one or more levels if there are concerns about any of the  
34 individual CERQual components. In line with advice from the CERQual developers,  
35 the overall assessment does not involve numerical scoring for each component but in  
36 order to ensure consistency across and between guidelines, the NGA established  
37 some guiding principles for overall ratings. For example, a review finding would not  
38 be downgraded (and therefore would be assessed with 'high' confidence) if all 4  
39 components had 'no or very minor' concerns or 3 'no or very minor' and 1 'minor'. At  
40 the other extreme, a review finding would be downgraded 3 times (to 'very low') if  
41 at least 2 components had serious concerns or at least 3 had moderate concerns. A  
42 basic principle was that if any components had serious concerns then overall  
43 confidence in the review finding would be downgraded at least once (potentially more  
44 depending on the other ratings). Transparency about overall judgements is provided  
45 in the CERQual tables, including a brief reference to components for which there  
46 were concerns in the 'overall confidence' cell.

1 **Table 5: Adaptation of GRADE quality elements for qualitative reviews**

Quality element	Description
Methodological limitations	Limitations in study design and implementation may bias interpretation of qualitative themes identified. High risk of bias for the majority of the evidence reduces our confidence that the review findings reflect the phenomena of interest.. Qualitative studies are not usually randomised and therefore would not be downgraded for study design from the outset (they start as high quality)
Relevance (or applicability) of evidence	This refers to the extent to which the context of the studies supporting the review findings is applicable to the context specified in the review question
Coherence of findings	This refers to the extent to which review findings are well grounded in data from the contributing primary studies and provide a credible explanation for patterns identified in the evidence. If the data from the underlying studies are ambiguous or contradict the review finding this would reduce our confidence in the finding
Adequacy of data (theme saturation or sufficiency)	This corresponds to a similar concept in primary qualitative research, that is, whether a theoretical point of theme saturation was achieved, at which point no further citations or observations would provide more insight or suggest a different interpretation of the particular theme. Judgements are not based on the number of studies but do take account of the quantity and also richness of data underpinning a finding. The more complex the finding, the more detail the supporting data need to be. For simple findings, relatively superficial data would be considered adequate to explain and explore the phenomenon being described.

2 **Table 6: CERQual levels of concern (by quality element)**

Level of concern	Definition
None or very minor concerns	Unlikely to reduce confidence in the review finding
Minor concerns	May reduce confidence in the review finding
Moderate concerns	Will probably reduce confidence in the review finding
Serious concerns	Very likely to reduce confidence in the review finding

3 **Table 7: Overall confidence in the evidence in CERQual (by review finding)**

Overall confidence level	Definition
High	It is highly likely that the review finding is a reasonable representation of the phenomenon of interest
Moderate	It is likely that the review finding is a reasonable representation of the phenomenon of interest
Low	It is possible that the review finding is a reasonable representation of the phenomenon of interest
Very low	It is unclear whether the review finding is a reasonable representation of the phenomenon of interest

1 *Assessing methodological limitations in qualitative reviews*

2 Methodological limitations in qualitative studies were assessed using the Critical  
3 Appraisal Skills Programme (CASP) checklist for qualitative studies ([see appendix H](#)  
4 [in Developing NICE guidelines: the manual](#)). Overall methodological limitations were  
5 derived by assessing the methodological limitations across the 6 domains  
6 summarised in Table 8.

7 **Table 8: Methodological limitations in qualitative studies**

Aim and appropriateness of qualitative evidence	This domain assesses whether the aims and relevance of the study were described clearly and whether qualitative research methods were appropriate for investigating the research question
Rigour in study design or validity of theoretical approach	This domain assesses whether the study approach was documented clearly and whether it was based on a theoretical framework (such as ethnography or grounded theory). This does not necessarily mean that the framework has to be stated explicitly, but a detailed description ensuring transparency and reproducibility should be provided
Sample selection	This domain assesses the background, the procedure and reasons for the method of selecting participants. The assessment should include consideration of any relationship between the researcher and the participants, and how this might have influenced the findings
Data collection	This domain assesses the documentation of the method of data collection (in-depth interviews, semi-structured interviews, focus groups or observations). It also assesses who conducted any interviews, how long they lasted and where they took place
Data analysis	This domain assesses whether sufficient detail was documented for the analytical process and whether it was in accordance with the theoretical approach. For example, if a thematic analysis was used, the assessment would focus on the description of the approach used to generate themes. Consideration of data saturation would also form part of this assessment (it could be reported directly or it might be inferred from the citations documented that more themes could be found)
Results	This domain assesses any reasoning accompanying reporting of results (for example, whether a theoretical proposal or framework is provided)

1 *Assessing relevance of evidence in qualitative reviews*

2 Relevance (applicability) of findings in qualitative research is the equivalent of  
3 indirectness for quantitative outcomes, and refers to how closely the aims and  
4 context of studies contributing to a theme reflect the objectives outlined in the  
5 guideline review protocol.

6 *Assessing coherence of findings in qualitative reviews*

7 For qualitative research, a similar concept to inconsistency is coherence, which  
8 refers to the way findings within themes are described and whether they make sense.  
9 This concept was used in the quality assessment across studies for individual  
10 themes. This does not mean that contradictory evidence was automatically  
11 downgraded, but that it was highlighted and presented, and that reasoning was  
12 provided. Provided the themes, or components of themes, from individual studies fit  
13 into a theoretical framework, they do not necessarily have to reflect the same  
14 perspective. It should, however, be possible to explain these by differences in context  
15 (for example, the views of healthcare professionals might not be the same as those  
16 of family members, but they could contribute to the same overarching themes).

17 *Assessing adequacy of data in qualitative reviews*

18 Adequacy of data (theme saturation or sufficiency) corresponds to a similar concept  
19 in primary qualitative research in which consideration is made of whether a  
20 theoretical point of theme saturation was achieved, meaning that no further citations  
21 or observations would provide more insight or suggest a different interpretation of the  
22 theme concerned. As noted above, it is not equivalent to the number of studies  
23 contributing to a theme, but it does take account of the quantity of data supporting a  
24 review finding (for instance whether sufficient quotations or observations were  
25 provided to underpin the findings) and in particular the degree of 'richness' of  
26 supporting data. Concerns about richness arise when insufficient details are provided  
27 by the data to enable an understanding of the phenomenon being described.  
28 Generally, if a review finding is simple then relatively superficial data will be needed  
29 to understand it. Data underpinning a more complex finding would need to offer  
30 greater detail, allowing for interpretation and exploration of the phenomenon being  
31 described. Therefore, in assessing adequacy our downgrading involved weighing up  
32 the complexity of the review finding against the explanatory contribution of the  
33 supporting data.

34 **Reviewing economic evidence**

35 Titles and abstracts of articles identified through the economic literature searches  
36 were independently assessed for inclusion using the predefined eligibility criteria  
37 listed in Table 9.

38 **Table 9: Inclusion and exclusion criteria for systematic reviews of economic**  
39 **evaluations**

Inclusion criteria
Intervention or comparators in accordance with the guideline scope.
Study population in accordance with the guideline scope.
Full economic evaluations (cost-utility, cost effectiveness, cost-benefit or cost-consequence analyses) assessing both costs and outcomes associated with interventions of interest.

#### Inclusion criteria

Cost analyses were also considered for inclusion due to the anticipated lack of economic evidence. Only costing studies after 2010 and from a UK perspective were included.

#### Exclusion criteria

Abstracts containing insufficient methodological details.

Cost-of-illness type studies.

- 1 Once the screening of titles and abstracts was completed, full-text copies of  
2 potentially relevant articles were requested for detailed assessment. Inclusion and  
3 exclusion criteria were applied to articles obtained as full-text copies.
- 4 Details of economic evidence study selection, lists of excluded studies, economic  
5 evidence tables, the results of quality assessment of economic evidence (see below)  
6 and economic modelling are presented in Supplement 2 (Economics).

### 7 Appraising the quality of economic evidence

- 8 The quality of economic evidence was assessed using the economic evaluations  
9 checklist specified in [Developing NICE guidelines: the manual](#).

## 10 Economic modelling

11 The aims of the economic input to the guideline were to inform the guideline  
12 committee of potential economic issues to ensure that recommendations represented  
13 a cost effective use of healthcare resources. Economic evaluations aim to integrate  
14 data on healthcare benefits (ideally in terms of quality-adjusted life-years; QALYs)  
15 with the costs of different options. In addition, the economic input aimed to identify  
16 areas of high resource impact; these are recommendations which (while cost  
17 effective) might have a large impact on Clinical Commissioning Group, Local  
18 Authority or Trust finances and so need special attention.

19 The guideline committee prioritised the following review questions for economic  
20 modelling where it was thought that economic considerations would be particularly  
21 important in formulating recommendations.

- 22 • Topic G: What is the effectiveness of social and community support  
23 approaches (including peer support) in promoting social inclusion of adults with  
24 complex needs?
- 25 • A number of costing analyses were also undertaken for potential  
26 recommendations which could have a resource impact.

27  
28 The methods and results of the de novo economic analyses and costing analyses are  
29 reported in Supplement 2 (Economics). When new economic analysis was not  
30 prioritised, the committee made a qualitative judgement regarding cost effectiveness  
31 by considering expected differences in resource and cost use between options,  
32 alongside effectiveness evidence identified from the evidence review.

### 33 Cost effectiveness criteria

- 34 NICE's report [Social value judgements: principles for the development of NICE](#)  
35 [guidance](#) sets out the principles that committees should consider when judging

1 whether an intervention offers good value for money. In general, an intervention was  
2 considered to be cost effective if any of the following criteria applied (provided that  
3 the estimate was considered plausible):

- 4 • the intervention dominated other relevant strategies (that is, it was both less  
5 costly in terms of resource use and more effective compared with all the other  
6 relevant alternative strategies)
- 7 • the intervention cost less than £20,000 per QALY gained compared with the  
8 next best strategy
- 9 • the intervention provided important benefits at an acceptable additional cost  
10 when compared with the next best strategy.

11 The committee's considerations of cost effectiveness are discussed explicitly under  
12 the heading 'Consideration of economic benefits and harms' in the relevant evidence  
13 reviews.

14 Details of the cost effectiveness analyses undertaken for the guideline are presented  
15 in Supplement 2 (Economics).

## 16 **Developing recommendations**

### 17 **Guideline recommendations**

18 Recommendations were drafted on the basis of the committee's interpretation of the  
19 available evidence, taking account of the balance of benefits, harms and costs  
20 between different courses of action. When effectiveness, qualitative and economic  
21 evidence was of poor quality, conflicting or absent, the committee drafted  
22 recommendations based on their expert opinion. The considerations for making  
23 consensus-based recommendations include the balance between potential benefits  
24 and harms, the economic costs or implications compared with the economic benefits,  
25 current practices, recommendations made in other relevant guidelines, person's  
26 preferences and equality issues.

27 The main considerations specific to each recommendation are outlined under the  
28 heading 'The committee's discussion of the evidence' within each evidence review.

29 For further details refer to [Developing NICE guidelines: the manual](#).

### 30 **Research recommendations**

31 When areas were identified for which evidence was lacking, the committee  
32 considered making recommendations for future research. For further details refer to  
33 [Developing NICE guidelines: the manual and NICE's Research recommendations  
34 process and methods guide](#).

## 35 **Validation process**

36 This guideline was subject to a 6-week public consultation and feedback process. All  
37 comments received from registered stakeholders were responded to in writing and  
38 posted on the NICE website at publication. For further details refer to [Developing  
39 NICE guidelines: the manual](#).

## 1 **Updating the guideline**

- 2 Following publication, NICE will undertake a surveillance review to determine
- 3 whether the evidence base has progressed sufficiently to consider altering the
- 4 guideline recommendations and warrant an update. For further details refer to
- 5 [Developing NICE guidelines: the manual](#).

## 6 **Funding**

- 7 The NGA was commissioned by NICE to develop this guideline.

# References

- 1  
2 **Bradburn 2007**  
3  
4 Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Localio, A. R. Much ado about nothing:  
5 A comparison of the performance of meta-analytical methods with rare events.  
6 *Statistics in Medicine*, 26, 53–77, 2007.
- 7 **Dixon-Woods 2005**  
8 Dixon-Woods M, Agarwal S, Jones D et al. (2005) Synthesising qualitative and  
9 quantitative evidence: a review of possible methods. *Journal of Health Services*  
10 *Research & Policy* 10(1), 45–53
- 11 **Hayden 2013**  
12 Jill A. Hayden, Danielle A. van der Windt, Jennifer L. Cartwright, Pierre Côté, Claire  
13 Bombardier. Assessing Bias in Studies of Prognostic Factors. *Ann Intern Med*.  
14 2013;158:280–286. doi: 10.7326/0003-4819-158-4-201302190-00009
- 15 **Higgins 2011**  
16 Higgins JPT, Green S (editors) (2011) *Cochrane Handbook for Systematic Reviews*  
17 *of Interventions Version 5.1.0 [updated 2019]* The Cochrane Collaboration. Available  
18 from [www.handbook.cochrane.org](http://www.handbook.cochrane.org) (accessed 17 August 2021)
- 19 **Lewin 2018**  
20 Lewin S, Booth A, Glenton C, Munthe-Kaas H et al. (2018) Applying GRADE-  
21 CERQual to qualitative evidence synthesis findings: introduction to the series.  
22 *Implement Sci*. 2018 Jan 25;13 (Suppl1):2
- 23 **McGowan 2016**  
24 McGowan J, Sampson M, Salzwedel DM et al. (2016) [PRESS Peer Review of](#)  
25 [Electronic Search Strategies: 2015 guideline statement](#). *Journal of Clinical*  
26 *Epidemiology* 75: 40–6
- 27 **NICE 2018**  
28 National Institute for Health and Care Excellence (NICE) (2014) NICE Policy on  
29 conflicts of interest (updated 2017). Available from  
30 [https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-](https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/declaration-of-interests-policy.pdf)  
31 [procedures/declaration-of-interests-policy.pdf](https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/declaration-of-interests-policy.pdf) (accessed 17 August 2021)
- 32 **Santesso 2016**  
33 Santesso N, Carrasco-Labra A, Langendam M et al. (2016) Improving GRADE  
34 evidence tables part 3: detailed guidance for explanatory footnotes supports creating  
35 and understanding GRADE certainty in the evidence judgments. *Journal of clinical*  
36 *epidemiology* 74, 28-39  
37